Healthcare Spending and Systemic Bevacizumab for Recurrent Respiratory Papillomatosis

Juvenile-onset recurrent respiratory papillomatosis (JoRRP) is a rare, costly condition linked to human papillomavirus. Standard of care is serial surgical debridement. Many adjunctive therapies have been trialed, with recent success with systemic bevacizumab. This paper examines healthcare spending associated with systemic bevacizumab use for JoRRP and compares it to healthcare spending for surgical care alone to determine whether bevacizumab has a financial benefit.

Source: Journal of Voice - April 25, 2024 Category: ENT & OMF Authors: Ari D. Schuman, Alyssa C. Chapel, Peng You, Rajkumar Venkatramani, Heidi V. Russell, Nikhila Raol, Julina Ongkasuwan Source Type: research